Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Tenaya Therapeutics, Inc. Stock

Equities

TNYA

US87990A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 02:18:55 2024-09-18 pm EDT 		5-day change 1st Jan Change
2.125 USD +2.66% Intraday chart for Tenaya Therapeutics, Inc. -5.00% -35.49%
Sep. 05 Transcript : Tenaya Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:00 AM
Aug. 08 Tenaya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Valuation: Tenaya Therapeutics, Inc.

(USD)
Capitalization 163M P/E ratio 2024 *
-1.42x
P/E ratio 2025 * -1.38x
Enterprise value 116M EV / Sales 2024 *
117x
EV / Sales 2025 * 21.4x
Free-Float
98.23%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Tenaya Therapeutics, Inc.

Dynamic Chart

Latest news: Tenaya Therapeutics, Inc.

Transcript : Tenaya Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:00 AM
Tenaya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Faraz Ali to Serve as Interim Principal Financial Officer of Tenaya Therapeutics, Inc., Effective August 14, 2024 CI
Tenaya Therapeutics, Inc. Announces Management Changes CI
Leone Patterson, Non-Executive Director, Leaves Tenaya Therapeutics, Inc., Effective 14 August 2024 CI
Tenaya Therapeutics, Inc. Announces Resignation of Leone Patterson as Chief Financial and Business Officer, Effective from August 14, 2024 CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell Microcap Growth Index CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell 2500 Growth Index CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell 3000E Growth Index CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell 3000 Growth Index CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell 2000 Growth Index CI
Tenaya Therapeutics, Inc.(NasdaqGS:TNYA) added to Russell Small Cap Comp Growth Index CI
Tenaya Therapeutics, Inc. Announces Research Leadership Updates CI
More news

Last Transcript: Tenaya Therapeutics, Inc.

Logo Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 07:00 AM
More transcripts

Analysts' recommendations: Tenaya Therapeutics, Inc.

William Blair Starts Tenaya Therapeutics With Outperform Rating MT
Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating MT
More recommendations

Press Releases: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate in Upcoming Investment Conferences AQ
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update AQ
Tenaya Therapeutics Announces Research Leadership Updates AQ
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit AQ
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update AQ
More press releases

Quotes and Performance

1 day+4.02%
1 week-10.00%
Current month-22.76%
1 month-28.37%
3 months-37.27%
6 months-58.39%
Current year-36.11%
More quotes

Course Extremes

1 week
1.88
Extreme 1.88
2.30
1 month
1.88
Extreme 1.88
3.05
Current year
1.88
Extreme 1.88
7.01
1 year
1.66
Extreme 1.66
7.01
3 years
1.64
Extreme 1.64
32.00
5 years
1.64
Extreme 1.64
32.00
10 years
1.64
Extreme 1.64
32.00
More quotes

Managers and Directors: Tenaya Therapeutics, Inc.

Director TitleAgeSince
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
Matthew Jay Pollman CTO
 Chief Tech/Sci/R&D Officer - -
Kee-Hong Kim CTO
 Chief Tech/Sci/R&D Officer - 18-09-30
Manager TitleAgeSince
Deepak Srivastava FOU
 Founder 57 16-09-30
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
David Goeddel CHM
 Chairman 72 16-07-31
More insiders

ETFs: Tenaya Therapeutics, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.01% 0 M€ 0.00% -
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD ETF Adaptive RH Hedged Multi-Asset Income ETF - USD
0.00% 17 M€ +6.15% -
More ETFs: Tenaya Therapeutics, Inc.

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
TENAYA THERAPEUTICS, INC. Stock Tenaya Therapeutics, Inc.
+4.02%-10.00%-35.51%-90.07%163M
LONZA GROUP AG Stock Lonza Group AG
-2.07%-1.46%+8.44%-28.35%46.01B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.25%+2.03%+13.35%-6.38%43.75B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+1.51%+7.12%+48.36%+44.19%35.24B
CELLTRION, INC. Stock Celltrion, Inc.
-0.20%-0.31%+33.24%-24.84%30.44B
MODERNA, INC. Stock Moderna, Inc.
+4.08%-9.20%-37.18%-83.26%27.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
-1.03%+4.30%+11.78%+9.08%24.23B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+0.01%+0.75%+56.66%+72.44%15.35B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.70%+2.03%+2.21%-43.65%11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-0.57%+8.19%+26.67%+90.65%10.97B
Average +0.67%+0.54%+12.80%-6.02% 24.58B
Weighted average by Cap. +0.22%+1.20%+16.80%-5.27%
See all sector performances

Financials

(USD)
2024 *2025 *
Net sales 833K 4.6M
Net income -124M -137M
Net Debt -65.56M -64.65M
More financial data * Estimated data

Company Profile

Logo Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Employees
140
Sector
Biotechnology & Medical Research
Calendar
2024-09-22 - World Medical Innovation Forum
More about the company

Quotes

Date Price Change Volume
24-09-18 2.090 $ +0.97% 173,819
24-09-17 2.070 $ +4.02% 689,489
24-09-16 1.990 $ -0.50% 627,044
24-09-13 2.000 $ -2.91% 1,094,619
24-09-12 2.060 $ -6.36% 622,927

Delayed Quote Nasdaq, September 17, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.070USD
Average target price
18.75USD
Spread / Average Target
+805.80%
Consensus
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TNYA Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW